肿瘤细胞治疗研究
英文原题：T cell immunotherapy for cervical cancer: challenges and opportunities.
肿瘤细胞免疫治疗在临床实践中取得了令人鼓舞的疗效，为宫颈癌的治愈带来了新希望。
肿瘤细胞免疫治疗在临床实践中已取得令人鼓舞的治疗效果，为宫颈癌的治愈带来了新希望。CD8+T细胞是抗肿瘤免疫中有效的细胞毒性效应细胞，基于T细胞的免疫治疗在细胞免疫治疗中起着至关重要的作用。TIL（肿瘤浸润淋巴细胞）作为天然T细胞，已被批准用于宫颈癌免疫治疗，工程化T细胞治疗也取得了令人瞩目的进展。具有天然或工程化肿瘤抗原结合位点的T细胞（CAR-T、TCR-T）在体外扩增，然后回输到患者体内以清除肿瘤细胞。本文综述了基于T细胞的免疫治疗在宫颈癌中的临床前研究和临床应用，以及宫颈癌免疫治疗面临的挑战。
Cancer cellular immunotherapy has made inspiring therapeutic effects in clinical practices, which brings new hope for the cure of cervical cancer. CD8+T cells are the effective cytotoxic effector cells against cancer in antitumor immunity, and T cells-based immunotherapy plays a crucial role in cellular immunotherapy. Tumor infiltrated Lymphocytes (TIL), the natural T cells, is approved for cervical cancer immunotherapy, and Engineered T cells therapy also has impressive progress. T cells with natural or engineered tumor antigen binding sites (CAR-T, TCR-T) are expanded in vitro , and re-infused back into the patients to eradicate tumor cells. This review summarizes the preclinical research and clinical applications of T cell-based immunotherapy for cervical cancer, and the challenges for cervical cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
